文献速递精神分裂症与精神病性障碍

基于功能连接组的神经特征可个体化预测首发精神病抗精神病药疗效

A Functional Connectome-Based Neural Signature for Individualized Prediction of Antipsychotic Response in First-Episode Psychosis.
PubMed 文献 · Am J Psychiatry · 2023-08-30

该研究在49例首发精神病患者中发现样本中,采用多范式fMRI基线的跨范式连接组预测建模,预测12周抗精神病单药治疗个体化精神病评分变化率,发现样本预测与观察值r=0.41,独立验证样本24例r=0.47,提示基于连接组的功能特征可作为早期个体化疗效预测生物标志物。

要点

  • 基线跨范式功能连接组特征可预测首发精神病患者12周抗精神病治疗个体化疗效。
  • 预测模型在发现样本(r=0.41)与独立验证样本(r=0.47)中均显示显著预测效能。
  • 正向预测精神病评分变化的连接主要涉及小脑-皮层环路,负向预测主要涉及皮层认知系统内连接。

核心结论

  • 基于功能连接组的神经特征可作为首发精神病患者抗精神病治疗个体化早期预测的有前景生物标志物。

研究设计与样本

  • 发现样本纳入49例首发精神病患者,基线接受多范式fMRI扫描,随后抗精神病单药治疗随访12周。
  • 采用跨范式连接与连接组预测建模,基于交叉验证训练模型预测个体化精神病评分变化率。
  • 独立验证样本纳入24例类似设计的首发精神病患者以检验模型泛化性。

主要发现

  • 发现样本中预测与观察的精神病评分变化率显著相关(r=0.41)。
  • 验证样本中预测与观察的精神病评分变化率显著相关(r=0.47,均方误差=0.019)。
  • 正向预测精神病评分变化的特征主要涉及小脑-皮层环路连接。
  • 负向预测精神病评分变化的特征主要为皮层认知系统内连接。

关键数值与推荐

  • 疗效评估基于简明精神病评定量表(BPRS)的精神病评分。
  • 模型性能以交叉验证下预测与观察变化率的Pearson相关系数评估。

临床怎么用

  • 该连接组特征有望在首发精神病早期辅助个体化预测抗精神病治疗反应,支持精准精神病学临床决策。

局限性

  • 发现样本49例、验证样本24例,样本量较小。
  • 随访12周,仅评估抗精神病单药治疗。
  • 需进一步外部独立验证以确认临床适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Identification of robust biomarkers that predict individualized response to antipsychotic treatment at the early stage of psychotic disorders remains a challenge in precision psychiatry. The aim of this study was to investigate whether any functional connectome-based neural traits could serve as such a biomarker. METHODS: In a discovery sample, 49 patients with first-episode psychosis received multi-paradigm fMRI scans at baseline and were clinically followed up for 12 weeks under antipsychotic monotherapies. Treatment response was evaluated at the individual level based on the psychosis score of the Brief Psychiatric Rating Scale. Cross-paradigm connectivity and connectome-based predictive modeling were employed to train a predictive model that uses baseline connectomic measures to predict individualized change rates of psychosis scores, with model performance evaluated as the Pearson correlations between the predicted change rates and the observed change rates, based on cross-validation. The model generalizability was further examined in an independent validation sample of 24 patients in a similar design. RESULTS: The results revealed a paradigm-independent connectomic trait that significantly predicted individualized treatment outcome in both the discovery sample (predicted-versus-observed r=0.41) and the validation sample (predicted-versus-observed r=0.47, mean squared error=0.019). Features that positively predicted psychosis change rates primarily involved connections related to the cerebellar-cortical circuitry, and features that negatively predicted psychosis change rates were chiefly connections within the cortical cognitive systems. CONCLUSIONS: This study discovers and validates a connectome-based functional signature as a promising early predictor for individualized response to antipsychotic treatment in first-episode psychosis, thus highlighting the potential clinical value of this biomarker in precision psychiatry.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cao H, Lencz T, Gallego JA, et al. A Functional Connectome-Based Neural Signature for Individualized Prediction of Antipsychotic Response in First-Episode Psychosis. Am J Psychiatry. 2023. PMID: 37644811. doi:10.1176/appi.ajp.20220719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。